OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
Forum of Clinical Oncology · 2015
DOI: 10.1515/fco-2015-0014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Forum of Clinical Oncology, 2015. Verfasst von Nikolaos Soupos und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer
Zitieren
APA
Soupos, N., Laschos, K., Bournakis, E., Kostouros, E., & Aravantinos, G. (2015). OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer. Forum of Clinical Oncology. https://doi.org/10.1515/fco-2015-0014
Vancouver
Soupos N, Laschos K, Bournakis E, Kostouros E, Aravantinos G. OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer. Forum of Clinical Oncology. 2015. doi:10.1515/fco-2015-0014
BibTeX
@article{Soupos2015,
author = {Soupos, Nikolaos and Laschos, Konstantinos and Bournakis, Evangelos and Kostouros, Euthymios and Aravantinos, Gerasimos},
title = {OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer},
journal = {Forum of Clinical Oncology},
year = {2015},
doi = {10.1515/fco-2015-0014}
}
EUVIMED